North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing 2
通过下一代外显子组测序进行北卡罗来纳州临床基因组评估 2
基本信息
- 批准号:10362100
- 负责人:
- 金额:$ 172.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-12-05 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressClinicalClinical DataCommunicationCommunitiesCopy Number PolymorphismCoupledData CollectionDevelopmentDiagnosisDiagnosticDifferential DiagnosisEnrollmentEnsureEvaluationFamilyFamily memberFosteringGeneticGenetic DiseasesGenetic HeterogeneityGenomic medicineGenomicsGeographyGrantHealth Care CostsHealthcareHealthcare SystemsInformed ConsentInterventionMassive Parallel SequencingMedicalMinority GroupsModalityModelingMolecular AnalysisMolecular DiagnosisNorth CarolinaOutcomeParticipantPatient Outcomes AssessmentsPatient-Focused OutcomesPatientsPatternPerformancePersonal SatisfactionPhase III Clinical TrialsPhenotypePhysiciansPopulationPreparationPreventionProcessProviderRandomized Clinical TrialsRandomized Controlled TrialsRare DiseasesResearchResearch DesignSiteTechnologyTestingThinkingThird-Party PayerUnderrepresented MinorityVisitbaseburden of illnesscare outcomesclinical applicationclinical careclinical implementationclinical sequencingcostcost effectivenessdata sharingdata standardsdisadvantaged populationeconomic implicationevidence baseexome sequencingexpectationexperiencefamily burdenfollow-upgenetic variantgenome sequencinggenome-widegenomic datahealth care service utilizationhealth disparityimprovedinnovationpatient responsepopulation healthprogramsrandomized controlled designsuccesstheoriestherapy designtooltreatment as usualtrial comparinguptakevariant detectionwhole genome
项目摘要
Project Summary/Abstract from original grant submission
Rapid development of genome sequencing technology has led to dramatic increases in the discovery of the
genetic causes of many rare disorders and has transformed our ability to diagnose and treat genetic
conditions. In particular, whole exome sequencing (WES) has proven to be a highly successful diagnostic
modality in patients with conditions having a high degree of genetic heterogeneity. As part of the Clinical
Sequencing Exploratory Research (CSER) consortium, UNC’s project, “North Carolina Clinical Genomic
Evaluation by Next-gen Exome Sequencing” (NCGENES) addressed several key issues in the clinical
application of exome sequencing, including the diagnostic yield when applying WES in diverse clinical
scenarios, optimal approaches to dealing with secondary findings, the informed consent process, and
responses of patients and families to genomic information. Due in part to the success of the CSER program,
WES has become widely clinically available. However, before it can be widely implemented payers will need to
be convinced to routinely cover the use of WES; thus, critical questions must be addressed regarding its
clinical utility. The current renewal, NCGENES 2, will provide this necessary evidence base by bringing
together a highly inter-disciplinary team to conduct a randomized clinical trial to study healthcare outcomes and
communication among patients, family members, clinicians, and laboratorians. Moreover, NCGENES 2 will
address these issues in traditionally disadvantaged populations to ensure that the benefits of genomic
medicine will accrue to the broadest possible segment of the population. Each aim of NCGENES 2 will
address specific outcomes that are highly relevant to the real-world implementation of clinical exome
sequencing: 1) technical and analytic outcomes, 2) patient-centered outcomes, 3) clinical outcomes, and 4)
societal outcomes, including economic implications. Ultimately, NCGENES 2 will generate the necessary
evidence to support the use of WES as a standard tool in the management of patients with genetic disorders
and enable its implementation in populations that experience health disparities.
项目摘要/原始赠款提交摘要
基因组测序技术的快速发展导致了发现的基因组DNA的急剧增加。
许多罕见疾病的遗传原因,并改变了我们诊断和治疗遗传疾病的能力。
条件特别是,全外显子组测序(WES)已被证明是一种非常成功的诊断方法。
在具有高度遗传异质性的病症的患者中的模态。进行临床
测序探索性研究(CSER)联合会,J.S.的项目,“北卡罗来纳州临床基因组
下一代外显子组测序评估”(NCGENES)解决了临床中的几个关键问题,
外显子组测序的应用,包括在各种临床应用WES时的诊断率
情景、处理次要发现的最佳方法、知情同意程序,以及
患者和家属对基因组信息的反应。部分由于CSER计划的成功,
WES已广泛用于临床。然而,在广泛实施之前,付款人需要
被说服,以定期涵盖使用水环境卫生服务;因此,关键问题必须解决,
临床应用目前的更新,NCGENES 2,将提供这一必要的证据基础,
组建一个高度跨学科的团队,进行随机临床试验,研究医疗保健结果,
患者、家庭成员、临床医生和实验室人员之间的沟通。此外,NCGENES 2将
解决这些问题,在传统上处于不利地位的人口,以确保基因组的好处,
医药将惠及尽可能多的人群。NCGENES 2的每个目标都将
解决与临床外显子组的现实世界实施高度相关的具体结果
排序:1)技术和分析结果,2)以患者为中心的结果,3)临床结果,以及4)
社会影响,包括经济影响。最终,NCGENES 2将产生必要的
支持使用WES作为遗传性疾病患者管理标准工具的证据
并使其能够在经历健康差异的人群中实施。
项目成果
期刊论文数量(32)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Incidental Findings with Genomic Testing: Implications for Genetic Counseling Practice.
- DOI:10.1007/s40142-015-0075-9
- 发表时间:2015
- 期刊:
- 影响因子:2.1
- 作者:Roche MI;Berg JS
- 通讯作者:Berg JS
Combination of exome sequencing and immune testing confirms Aicardi-Goutières syndrome type 5 in a challenging pediatric neurology case.
外显子组测序和免疫检测相结合,在一个具有挑战性的儿科神经病学病例中证实了 5 型 Aicardi-Goutières 综合征。
- DOI:10.1101/mcs.a002758
- 发表时间:2018
- 期刊:
- 影响因子:1.8
- 作者:Haskell,GloriaT;Mori,Mari;Powell,Cynthia;Amrhein,TimothyJ;Rice,GillianI;Bailey,Lauren;Strande,Natasha;Weck,KarenE;Evans,JamesP;Berg,JonathanS;Kishnani,Priya
- 通讯作者:Kishnani,Priya
Genomic screening of the general adult population: key concepts for assessing net benefit with systematic evidence reviews.
- DOI:10.1038/gim.2014.129
- 发表时间:2015-06
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Defining the Clinical Value of a Genomic Diagnosis in the Era of Next-Generation Sequencing.
定义下一代测序时代基因组诊断的临床价值。
- DOI:10.1146/annurev-genom-083115-022348
- 发表时间:2016-08-31
- 期刊:
- 影响因子:8.7
- 作者:Strande NT;Berg JS
- 通讯作者:Berg JS
A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing.
- DOI:10.1038/gim.2015.104
- 发表时间:2016-05
- 期刊:
- 影响因子:0
- 作者:Berg JS;Foreman AK;O'Daniel JM;Booker JK;Boshe L;Carey T;Crooks KR;Jensen BC;Juengst ET;Lee K;Nelson DK;Powell BC;Powell CM;Roche MI;Skrzynia C;Strande NT;Weck KE;Wilhelmsen KC;Evans JP
- 通讯作者:Evans JP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JONATHAN S BERG其他文献
JONATHAN S BERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JONATHAN S BERG', 18)}}的其他基金
Educational Pathways to increase Diversity in Genomics (EDGE) at UNC Chapel Hill
北卡罗来纳大学教堂山分校增加基因组学多样性的教育途径 (EDGE)
- 批准号:
10347897 - 财政年份:2022
- 资助金额:
$ 172.87万 - 项目类别:
Educational Pathways to increase Diversity in Genomics (EDGE) at UNC Chapel Hill
北卡罗来纳大学教堂山分校增加基因组学多样性的教育途径 (EDGE)
- 批准号:
10563163 - 财政年份:2022
- 资助金额:
$ 172.87万 - 项目类别:
Age-based genomic screening in newborns, infants, and children: a novel paradigm in public health genomics
新生儿、婴儿和儿童基于年龄的基因组筛查:公共卫生基因组学的新范例
- 批准号:
10518804 - 财政年份:2022
- 资助金额:
$ 172.87万 - 项目类别:
Age-based genomic screening in newborns, infants, and children: a novel paradigm in public health genomics
新生儿、婴儿和儿童基于年龄的基因组筛查:公共卫生基因组学的新范例
- 批准号:
10705830 - 财政年份:2022
- 资助金额:
$ 172.87万 - 项目类别:
The Clinical Genome Resource – Advancing genomic medicine through biocuration and expert assessment of genes and variants at scale
临床基因组资源 — 通过大规模基因和变异的生物管理和专家评估推进基因组医学
- 批准号:
10472668 - 财政年份:2017
- 资助金额:
$ 172.87万 - 项目类别:
The Clinical Genome Resource – Advancing genomic medicine through biocuration and expert assessment of genes and variants at scale
临床基因组资源 — 通过大规模基因和变异的生物管理和专家评估推进基因组医学
- 批准号:
10669089 - 财政年份:2017
- 资助金额:
$ 172.87万 - 项目类别:
The Clinical Genome Resource – Advancing genomic medicine through biocuration and expert assessment of genes and variants at scale
临床基因组资源 — 通过大规模基因和变异的生物管理和专家评估推进基因组医学
- 批准号:
10606182 - 财政年份:2017
- 资助金额:
$ 172.87万 - 项目类别:
Administrative Supplement: The Clinical Genome Resource - Advancing genomic medicine through biocuration and expert assessment of genes and variants at scale
行政补充:临床基因组资源 - 通过大规模基因和变异的生物管理和专家评估推进基因组医学
- 批准号:
10841906 - 财政年份:2017
- 资助金额:
$ 172.87万 - 项目类别:
The Clinical Genome Resource – Advancing genomic medicine through biocuration and expert assessment of genes and variants at scale
临床基因组资源 — 通过大规模基因和变异的生物管理和专家评估推进基因组医学
- 批准号:
10270142 - 财政年份:2017
- 资助金额:
$ 172.87万 - 项目类别:
The Clinical Genome Resource - Expert Curation and EHR Integration
临床基因组资源 - 专家管理和 EHR 集成
- 批准号:
9759954 - 财政年份:2017
- 资助金额:
$ 172.87万 - 项目类别:
相似国自然基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE
NNTC 收集、存储和提供临床数据和特征明确的生物样本,包括来自研究志愿者和/或艾滋病毒感染者和艾滋病毒阴性者的器官捐献者的死后组织
- 批准号:
10934920 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE
NNTC 收集、存储和提供临床数据和特征明确的生物样本,包括来自研究志愿者和/或艾滋病毒感染者和艾滋病毒阴性者的器官捐献者的死后组织
- 批准号:
10934926 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE
NNTC 收集、存储和提供临床数据和特征明确的生物样本,包括来自研究志愿者和/或艾滋病毒感染者和艾滋病毒阴性者的器官捐献者的死后组织
- 批准号:
10945539 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE
NNTC 收集、存储和提供临床数据和特征明确的生物样本,包括来自研究志愿者和/或艾滋病毒感染者和艾滋病毒阴性者的器官捐献者的死后组织
- 批准号:
10934927 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE
NNTC 收集、存储和提供临床数据和特征明确的生物样本,包括来自研究志愿者和/或艾滋病毒感染者和艾滋病毒阴性者的器官捐献者的死后组织
- 批准号:
10945543 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
Core B-Clinical Data Collection and Management Core
核心 B-临床数据收集和管理核心
- 批准号:
10555683 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
Point-of-care prognostic modeling of PTSD risk after traumatic event exposure using digital biomarkers and clinical data from electronic health records in the emergency department setting (PREDICT)
使用数字生物标志物和急诊科电子健康记录中的临床数据对创伤事件暴露后的 PTSD 风险进行护理点预后建模 (PREDICT)
- 批准号:
10884738 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
使用 CTCAE 和其他临床数据分析和解释 PRO-CTCAE,以表征药物耐受性
- 批准号:
10884103 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE
NNTC 收集、存储和提供临床数据和特征明确的生物样本,包括来自研究志愿者和/或艾滋病毒感染者和艾滋病毒阴性者的器官捐献者的死后组织
- 批准号:
10934921 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别:
STSS TASK ORDER - NATIONAL CLINICAL DATA COLLABORATIVE (NACDAC)
STSS 任务单 - 国家临床数据协作组织 (NACDAC)
- 批准号:
10949868 - 财政年份:2023
- 资助金额:
$ 172.87万 - 项目类别: